JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week.

Leading the pack was the 53% jump by Insmed Inc. (NASDAQ:INSM), which announced 4Q18 sales of Arikayce amikacin liposome inhalation suspension of $9.8 million. Of that, $9.2 million came from the U.S., where FDA approved the antibiotic to treat Mycobacterium avium complex lung disease on Sept. 28. The rest come from an expanded access program in France...